Jennifer Couzin-Frankel

Oct 5, 2023 | urldefense.com | Jennifer Couzin-Frankel

For cardiologist Eric Topol, this week’s vaccine news presented a personal dilemma. Topol, who directs the Scripps Research Translational Institute and is a popular commenter on COVID-19 research, had hoped to get an updated COVID-19 vaccine from Novavax, rather than a messenger RNA (mRNA) shot from Pfizer or Moderna. Novavax relies on an older, protein-based approach that has shown long-lasting effects against other pathogens, and Topol wondered whether it might produce more durable protection.

Aug 7, 2023 | science.org | Meredith Wadman |Jennifer Couzin-Frankel

Last week, the family of Henrietta Lacks settled its lawsuit against the huge biotechnology company Thermo Fisher Scientific over its claim that the company had been “unjustly enriched” by its use of her cells.

Aug 2, 2023 | science.org | Jennifer Couzin-Frankel

A sea change is underway in the treatment of Alzheimer’s disease, where for the first time a drug that targets the disease’s pathology and clearly slows cognitive decline has hit the U.S. market. A related therapy will likely be approved in the coming months.

Aug 1, 2023 | tinyurl.com | Jennifer Couzin-Frankel |Kelly Servick |Emily Underwood

A sea change is underway in the treatment of Alzheimer’s disease, where for the first time a drug that targets the disease’s pathology and clearly slows cognitive decline has hit the U.S. market. A related therapy will likely be approved in the coming months.

Aug 1, 2023 | science.org | Jennifer Couzin-Frankel

The National Institutes of Health (NIH) yesterday announced new clinical trials to test a diverse array of treatment strategies—from an intravenous immune drug to light therapy and a dietary supplement—in people with Long Covid, the disabling syndrome that can follow infection with the pandemic coronavirus. The focus is on mitigating some of the most common and debilitating symptoms including brain fog and sleep troubles.